Home > Insider Trading > Filing (0001140361-15-014356)

Filing Details

Accession Number:: 0001140361-15-014356
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-04-03 15:42:51
Reporting Period:: 2015-04-01

Filing Date:: 2015-04-03
Accepted Time:: 2015-04-03 15:42:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1553352	A. John Lewicki	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063	Evp & Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-04-01	8,500	$1.43	29,785	No	4	M	Direct
Common Stock	Disposition	2015-04-01	8,500	$25.19	21,285	No	4	S	Direct
Common Stock	Acquisiton	2015-04-02	8,500	$1.43	29,785	No	4	M	Direct
Common Stock	Disposition	2015-04-02	6,940	$25.29	22,845	No	4	S	Direct
Common Stock	Disposition	2015-04-02	1,560	$25.70	21,285	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2015-04-01	8,500	$0.00	8,500	$1.43
Common Stock	Stock Option (Right to Buy)	Acquisiton	2015-04-02	8,500	$0.00	8,500	$1.43

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,777		2017-01-11	No	4	M	Direct
23,277		2017-01-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	83,530	Indirect	See Footnote

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2014.
Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
Includes 1,285 shares acquired under the Issuer's Employee Stock Purchase Plan on February 27, 2015.
This transaction was executed in multiple trades in prices ranging from $24.63 to $25.56, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $24.62 to $25.61, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $25.62 to $26.12, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.
The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.